Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole-Reference-Cited by-同舟云学术

Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole

Published:2013-04-12 Issue:7 Volume:41 Page:1329-1338
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Han Bing,Mao Jialin,Chien Jenny Y.,Hall Stephen D.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference23 articles.

1. STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE

2. Comparison of midazolam and simvastatin as cytochrome P450 3A probes

3. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity;Eap;Eur J Clin Pharmacol,2004

4. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257–1294.

5. FDA (2012) Drug Interaction Studies —Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362pdf .

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs;Clinical Pharmacokinetics;2022-09-03

2. Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib;Cancer Chemotherapy and Pharmacology;2020-09-04

3. Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model;Clinical Pharmacokinetics;2020-04-27

4. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling;The Journal of Clinical Pharmacology;2020-02-20

5. Isolation, analysis and in vitro assessment of CYP3A4 inhibition by methylxanthines extracted from Pu-erh and Bancha tea leaves;Scientific Reports;2019-09-26